2017 American Society of Clinical Oncology Annual Meeting*

Download All
June 2-6, 2017; Chicago, Illinois
Ursula Matulonis, MD, reviews key gynecologic cancer findings presented at the 2017 American Society of Clinical Oncology Annual Meeting.

Gynecologic Cancers

In the phase III LION trial, systemic pelvic and para-aortic lymphadenectomy offered no survival benefit and increased postoperative morbidity and mortality in patients with advanced ovarian cancer, macroscopic complete resection, and clinically/radiographically negative lymph nodes.

Released: June 5, 2017

Combination RT + CT improved 5-year failure-free survival by 11% in patients with stage III disease.

Released: June 4, 2017

Nivolumab monotherapy active with a manageable safety profile in recurrent/metastatic cervical, vaginal, or vulvar cancer regardless of PD-L1 expression.

Released: June 4, 2017

No detrimental effect on HRQoL, significant improvement in patient-centered benefits with olaparib vs placebo despite higher olaparib-associated toxicity.

Released: June 13, 2017
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants by
Celgene Corporation
Halozyme Therapeutics
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.